Company intelligence / Profile preview

Clexio Biosciences

Petach Tikva, Jerusalem Area, Israelclexio.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Lead drug candidate CLE-100 is in Phase 2 multicenter studies in the United States for Major Depressive Disorder. CLE-400 has completed Multiple Ascending Dose studies and is Phase 2 ready for Chronic Pruritus indications. CLE-500 is in Phase 1 for Cluster Headache. CLE-600 is in Phase 2 for Parkinson's Disease. CLE-905 has completed IND enabling activities with First-In-Human Phase 1 study expected to start soon.

Therapeutic areas: DermatologyPsychiatryNeurology
Modalities: Small moleculesdrug-device combinations
Industry: Biotech

Drug pipeline

5 assets

CLE-100

4 more assets in the full pipeline.

Request access →

Partnerships

Genetika+ (partnering to screen and characterize Clexio's antidepressant pipeline using Genetika+'s iPSC-derived neurons platform)

Beyond the preview

Go deeper on Clexio Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clexio Biosciences.

Explore the full profile